Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohort.

Puntos clave

• This study aims to identify the factors leading to discontinuation of long-acting cabotegravir plus rilpivirine therapy in HIV care.
• Analyzed data from the RELATIVITY cohort
• Evaluated persistence and tolerability of LAI-CAB+RPV
• Examined rates of viral failure and reasons for discontinuation
• LAI-CAB+RPV showed strong persistence and low viral failure rates
• Discontinuations were primarily due to structural factors
• Need for improved continuity-of-care pathways was emphasized